Acetylfentanyl
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Acetylfentanyl is a synthetic opioid of the anilidopiperidine class. It is the simplest structural analog of fentanyl, distinguished by lower potency and a disproportionately narrow safety margin. Acetylfentanyl is a full agonist at µ-opioid receptors, producing its effects by suppressing pain signaling and depressing respiratory drive.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
fentanyl, morphine, heroin +4 morefentanyl, morphine, heroin, oxycodone, hydromorphone, methadone, all mu-opioid receptor agonists show less
Synthesized in the late 1960s by Janssen and Gardocki during structure-activity investigations of the fentanyl series,[3][4] acetylfentanyl was never developed for medical use and remained obscure for four decades. It surfaced on illicit markets in 2012–2013, triggering an outbreak of 14 overdose deaths in Rhode Island within three months.[5] It is now Schedule I in the United States and controlled in most major jurisdictions, though largely displaced from the drug supply by fentanyl itself.
Subjective effects include profound analgesia, euphoria, sedation, and anxiolysis. The experience mirrors fentanyl — a rapid dissolving of pain and distress into heavy warmth and narrowed consciousness — compressed into a shorter window. Nausea, respiratory slowing, and cognitive impairment are characteristic unsought effects.
Acetylfentanyl produces rapid physical dependence, and its therapeutic index is 23 times narrower than fentanyl's and 10 times narrower than morphine's.[6][3] Tolerance to euphoria and analgesia develops faster than tolerance to respiratory depression, meaning dose escalation progressively closes the already slim margin between intended effect and fatal overdose. No controlled human studies of any kind have been published — the entire evidence base consists of forensic case reports, postmortem toxicology, and animal pharmacology.
History[edit]
Discovery
Acetylfentanyl was first synthesized in the late 1960s by Janssen and Gardocki as part of systematic structure-activity studies of the anilidopiperidine series.[4][3] The compound — fentanyl with a single carbon removed from its acyl chain — was found to be less potent than the parent drug and was not pursued for clinical development. It remained an obscure laboratory entry for approximately four decades.
Illicit market emergence
Acetylfentanyl appeared on illicit drug markets in 2012–2013, initially sold online as a "research chemical" with manufacturing concentrated in China.[3][4] Its public health impact was immediate: 14 overdose deaths occurred in Rhode Island between March and May 2013,[5] prompting emergency scheduling action. By 2015, the EMCDDA–Europol joint report documented 32 fatalities across four EU member states,[7] and the compound had been detected in heroin supplies across multiple US states.[8]
Scheduling and decline
The United States temporarily placed acetylfentanyl in Schedule I in July 2015 and permanently scheduled it in June 2017, citing over 57 confirmed deaths.[9] By 2016–2017, acetylfentanyl's role had shifted from standalone product to manufacturing byproduct — appearing primarily as a minor contaminant in illicit fentanyl batches,[10] with mean blood concentrations in fatalities dropping from 8.9 ng/mL to 0.9 ng/mL as fentanyl itself dominated the supply.
The name "acetylfentanyl" derives directly from its structural relationship to fentanyl: the acetyl group (two-carbon acyl chain) replaces fentanyl's propionyl group (three carbons). Unlike fentanyl, which accumulated dozens of street names across decades of clinical and illicit use, acetylfentanyl has no widely recognized slang terminology — a reflection of its brief window as a standalone market product before being absorbed into the broader illicit fentanyl supply. Its principal legacy in drug culture is as an early warning signal: the 2013 Rhode Island cluster was among the first events to demonstrate that novel fentanyl analogs could appear on unregulated markets with lethal speed.
Chemistry[edit]
Structural class
Acetylfentanyl belongs to the anilidopiperidine class of synthetic opioids, a family built on a 4-anilidopiperidine core with an N-2-phenylethyl substituent. This scaffold, first explored by Paul Janssen in the 1960s, produced fentanyl and its clinical derivatives (sufentanil, alfentanil, remifentanil). Acetylfentanyl is the simplest N-acyl variation of fentanyl: where fentanyl carries a three-carbon propionyl group on the anilide nitrogen, acetylfentanyl carries a two-carbon acetyl group.[4][3]
This single-carbon difference reduces opioid receptor potency by approximately threefold relative to fentanyl.[11] Structure-activity studies of the anilidopiperidine series established that N-acyl chain length is a primary determinant of potency at the μ-opioid, with acetylfentanyl representing the lower boundary of clinically significant activity within the series.
Molecular properties
| Molecular formula | C₂₁H₂₆N₂O |
| Molecular weight | 322.4 g/mol |
The molecule comprises three pharmacophoric elements essential for mu-opioid receptor recognition: a phenethyl group at the piperidine nitrogen, a central piperidine ring, and an acylanilide (N-phenylacetamide) at the 4-position. Acetylfentanyl is achiral — it contains no asymmetric carbon centers, so no enantiomers exist and stereochemistry does not affect its activity.
Physical properties
As an anilidopiperidine, acetylfentanyl exhibits high lipophilicity — a class property enabling rapid blood-brain barrier penetration and significant brain accumulation, confirmed by postmortem studies showing brain concentrations exceeding those in peripheral blood.[12] No peer-reviewed data on melting point, solubility, or partition coefficient have been published.
Pharmacology[edit]
Mechanism of action
Acetylfentanyl is a full agonist at the μ-opioid (MOR), the molecular target responsible for its analgesic, euphoric, and respiratory depressant effects.[1][2] Binding at MOR activates inhibitory G-protein signaling, reducing neuronal excitability and suppressing synaptic transmission in pain-processing, reward, and respiratory control circuits.
No receptor binding affinity data have been published for acetylfentanyl. Potency estimates derive entirely from animal studies and cell-based assays. In cell-based functional assays, acetylfentanyl ranks below fentanyl and several other analogs in MOR agonist activity,[13] a rank order that extends to their metabolites.[14]
In mice, acetylfentanyl is approximately 15–16 times more potent than morphine and roughly one-third as potent as fentanyl.[11] The murine therapeutic index (LD₅₀/ED₅₀ ≈ 443) is 23 times narrower than fentanyl's and 10 times narrower than morphine's[6][3] — meaning the distance between an effective dose and a lethal dose is far smaller than for either reference compound.
Pharmacokinetics
No human pharmacokinetic studies have been published. Available data derive from forensic cases, animal studies, and structural analogy to fentanyl.
Absorption and distribution: As a highly lipophilic anilidopiperidine, acetylfentanyl rapidly crosses the blood-brain barrier. Postmortem studies confirm preferential brain accumulation, with brain tissue concentrations exceeding those in peripheral blood.[12]
Metabolism: Acetylfentanyl undergoes hepatic metabolism characterized in liver-humanized mouse models.[15] Primary Phase I reactions include hydrolysis of the acetamide bond (yielding 4-ANPP, a controlled fentanyl precursor), N-dealkylation, and hydroxylation at the piperidine and phenyl rings.[16] Phase II reactions include glucuronide and sulfate conjugation. Detection of 4-ANPP in urine confirms acetylfentanyl exposure.[17]
Elimination: No data on half-life or excretion pathways have been published. Acetylfentanyl is stable in blood specimens for up to 9 months under refrigerated and room-temperature storage.[18]
Neuroscience[edit]
Where it acts
Acetylfentanyl engages the same mesolimbic and mesocortical opioid circuits as all μ-opioid agonists. MOR activation in the ventral tegmental area disinhibits dopamine neurons projecting to the nucleus accumbens, producing reinforcing euphoria. Simultaneously, MOR agonism in the periaqueductal gray activates descending pain-inhibitory pathways, generating analgesia. The lethal mechanism — respiratory depression — originates from MOR activation in the pre-Bötzinger complex and other brainstem respiratory nuclei, which generate breathing rhythm; their suppression reduces respiratory rate and can produce apnea.
Why it matters
Two frameworks illuminate acetylfentanyl's dependence risk. Incentive salience theory predicts that repeated exposure sensitizes the "wanting" pathway (dopaminergic drive to seek the drug) faster than it tolerates the "liking" pathway (hedonic reward), producing escalating drug-seeking with diminishing subjective return. The allostatic load model adds that chronic MOR activation upregulates stress systems in the extended amygdala, shifting the hedonic baseline below normal — use becomes motivated by avoidance of withdrawal misery rather than pursuit of pleasure.
Key unresolved questions include whether acetylfentanyl's shorter acyl chain alters how long it occupies the mu-opioid receptor, potentially explaining its disproportionately narrow therapeutic index. It also remains unknown whether the divergence between pain-relieving and respiratory-depressant potency across the N-acyl fentanyl series[19] reflects differences in receptor signaling bias or differences in drug delivery to the brainstem versus the spinal cord. No neuroimaging studies of acetylfentanyl in humans or animals have been published.
Subjective Effects[edit]
Acetylfentanyl produces a classical μ-opioid experience: a rapid-onset dissolving of physical pain and emotional distress into undifferentiated warmth, heavy sedation, and narrowed consciousness. At threshold doses the effect is mild analgesia and calm; as dose increases, sedation deepens rapidly toward cognitive and physical incapacitation. The experience is heavily route-dependent, with insufflation producing a faster, more pronounced initial rush than sublingual administration.
Relative to fentanyl, acetylfentanyl is roughly one-third as potent per milligram but paradoxically more dangerous per unit of intended effect, owing to its disproportionately narrow therapeutic index. Compared to morphine, it is faster in onset, shorter in duration, and carries a safety margin 10 times narrower — leaving essentially no room for dosing error.
Effect Grid
At common doses, the full opioid effect constellation manifests: pronounced euphoria, significant sedation, and strong analgesia. Anxiety suppression is marked — emotional suppression flattens affective range, producing a state of insulated tranquility. Cognitive euphoria is prominent but accompanied by cognitive impairment: thought deceleration, reduced decision-making capacity, and focus suppression.
Physically, sedation dominates. Body high intensifies with strong tactile euphoria and spontaneous body sensations of warmth. Pupil constriction is clearly visible. Muscle relaxation is significant. Nausea becomes more likely, particularly in less tolerant individuals. Constipation, dry mouth, and appetite suppression are common. Respiratory depression becomes clinically relevant at this tier — monitoring is advisable.
Duration is 1–4 hours. Functional impairment is substantial. The compulsive redosing urge may emerge as effects begin to wane. Sexual arousal suppression is typical.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Bodily heaviness · Breathing alteration · Constipation · Muscle relaxation · Tactile euphoria · Nausea · Physical fatigue · Spontaneous body sensations · Dizziness · Dry mouth · Sexual arousal suppression · Temperature dysregulation · Appetite suppression · Excessive sweating · Heart rate perception changes · Vomiting · Yawning · Bodily lightness · Tingling / electric sensations · Watery eyes · Abnormal heartbeat · Involuntary body movements
Constipation · Muscle relaxation · Tactile euphoria · Nausea · Physical fatigue · Spontaneous body sensations · Dizziness · Dry mouth · Sexual arousal suppression · Appetite suppression · Excessive sweating · Heart rate perception changes · Vomiting · Yawning · Bodily lightness · Tingling / electric sensations · Watery eyes · Abnormal heartbeat · Involuntary body movements
Information processing suppression · Thought deceleration · Motivation suppression · Analysis suppression · Creativity suppression · Focus suppression · Language suppression · Memory suppression · Confusion · Memory fragmentation · Novelty suppression · Pattern recognition suppression · Suggestibility enhancement · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia
Analysis suppression · Creativity suppression · Focus suppression · Language suppression · Memory suppression · Confusion · Memory fragmentation · Novelty suppression · Pattern recognition suppression · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia
Dysphoria
Social disconnection · Social connection · Sociability enhancement · Cognitive disconnection
Timeline
Rapid rush of warmth and euphoria within 7–10 minutes. Onset is notably faster than sublingual, with a more pronounced initial wave. Analgesia and anxiolysis begin quickly.
Full opioid effect — sedation, euphoria, analgesia, and respiratory depression at maximum intensity. Pupil constriction is pinpoint. Cognitive impairment, thought deceleration, and emotional suppression are prominent.
Gradual waning of effects over 60–90 minutes. Residual sedation and mild analgesia persist. Compulsive redosing urge may peak during this phase as euphoria diminishes.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- fentanyl · morphine · heroin
Toxicity
Acute toxicity
Acetylfentanyl carries high acute toxicity with a critically narrow margin between an effective and a lethal dose. The therapeutic index (LD₅₀/ED₅₀ ≈ 443 in mice) is 23 times narrower than fentanyl's and 10 times narrower than morphine's.[6][3][11] The primary mechanism of death is respiratory depression progressing to respiratory arrest.[5][8][20]
Fatal blood concentrations vary enormously. Single-agent fatalities have shown levels around 250–270 ng/mL,[21][6] but polysubstance fatalities span a vast range (0.13–2100 ng/mL).[20][22] In one Pennsylvania series of 41 deaths, the median blood concentration was just 11 ng/mL, and 96% of cases involved multiple drugs.[20]
This extreme variability reflects the dominant role of co-intoxicants and individual opioid tolerance. Impaired driving cases in living subjects have shown levels as low as 1.0–9.2 ng/mL.[23] The compound accumulates preferentially in brain tissue,[12] consistent with its high lipophilicity.
Chronic toxicity
No published data exist on chronic organ toxicity specific to acetylfentanyl. By opioid class extrapolation, chronic use is expected to produce immune suppression, hormonal disruption, and gastrointestinal complications.inferred
Dermal exposure
The claim that incidental skin contact can cause fatal overdose is consistent with regulatory statements but no peer-reviewed case reports of fatal dermal absorption of acetylfentanyl specifically have been published.safety citation needed
Psychological risks
No controlled data on acetylfentanyl-specific psychological effects exist. Class-level risks of μ-opioid agonists include:
- Compulsive redosing driven by reinforcing euphoria and rapid tolerance
- Cognitive impairment during intoxication, including impaired judgment
- Severe mood disturbance during withdrawal, including anxiety, irritability, and inability to experience pleasure
- Suicidal ideation associated with withdrawal and chronic opioid use disorder
Documented cases uniformly involve loss of consciousness and deep sedation,[24][2] making psychological effects at sub-sedating doses impossible to assess from available data.
Tolerance and dependence
Tolerance to acetylfentanyl's analgesic and euphoric effects develops with repeated use through mu-opioid receptor desensitization. Cross-tolerance extends to all opioids. Tolerance half-life is estimated at approximately 5 days, with full reset in approximately 1.5 weekssafety citation needed — these values are class-level estimates and have not been verified for acetylfentanyl specifically.
Physical dependence develops with repeated use. Stopping produces a withdrawal syndrome characterized by intense discomfort, runny nose, watering eyes, sweating, goosebumps, muscle pain, diarrhea, nausea, and insomnia.inferred
Dependence liability is classified as extremely high. The DEA permanently scheduled acetylfentanyl in Schedule I partly on the basis of its high abuse potential.[9] Reinforcing properties of fentanyl analogs including acetylfentanyl have been specifically investigated in the context of illicit drug market substances.[25]
Drug interactions
The dominant interaction risk is synergistic respiratory depression when combined with other central nervous system depressants. This mechanism accounts for the majority of documented fatalities — 96% of deaths in one major series involved multiple drugs.[20]
Alcohol: Synergistic respiratory and CNS depression. Documented in multiple fatality series.[20]
Benzodiazepines: Combined respiratory depression. Documented fatalities include cases with alprazolam at toxic concentration alongside acetylfentanyl and fentanyl.[22]
GHB/GBL: Synergistic respiratory depression via complementary mechanisms. Classification: lethal risk.
Ketamine: Documented in overdose cases.[24] Synergistic respiratory depression and loss of protective airway reflexes.
Tramadol: Dual risk — combined mu-opioid agonism compounded by potential serotonergic interaction. Classification: lethal risk.
CYP3A4 inhibitors: By analogy to fentanyl, inhibitors such as ketoconazole, ritonavir, and erythromycin could theoretically increase acetylfentanyl levels and worsen respiratory depression.inferred
Contraindications
No acetylfentanyl-specific contraindication studies have been published. The following are derived from mu-opioid agonist class pharmacologyinferred:
Absolute contraindications:
- Respiratory compromise: Any pre-existing breathing difficulty (COPD, sleep apnea, pneumonia, asthma flare) dramatically increases fatal overdose risk, as respiratory depression is the primary lethal mechanism.
- Concurrent depressant use: Co-administration with benzodiazepines, alcohol, GHB/GBL, barbiturates, or other opioids carries lethal synergistic respiratory depression risk.[20]
- Opioid-naïve individuals at tolerant-user doses: The narrow therapeutic index makes dose miscalculation disproportionately lethal.
Relative contraindications:
- Liver impairment: Acetylfentanyl is hepatically metabolized; impaired clearance could prolong and intensify effects.inferred
- Head injury or raised pressure in the skull: Opioid-induced respiratory depression causes CO₂ buildup and brain swelling, potentially worsening intracranial pressure.inferred
- Pregnancy: Opioid agonists cross the placenta and can cause neonatal withdrawal syndrome.inferred
Harm Reduction[edit]
Forms & Identification
Acetylfentanyl cannot be visually distinguished from fentanyl, heroin, or other white-to-off-white powders by appearance alone. Because it increasingly appears as a contaminant in illicit fentanyl production rather than a standalone product,[3] users may encounter it without knowing. Fentanyl test strips detect acetylfentanyl, but a positive result does not distinguish between fentanyl and its analogs — it confirms the presence of an anilidopiperidine. Any powder suspected to contain an opioid should be tested. A negative test strip result does not guarantee safety, as test sensitivity varies by analog and concentration.
Guidelines
- Test all substances with fentanyl test strips before use
- Start with the smallest amount technically measurable — the therapeutic index does not forgive estimation
- Never use alone; ensure a sober person with naloxone is present
- Keep naloxone (Narcan) immediately accessible — not in another room, not in a bag
- Avoid mixing with any other depressant, including alcohol
- Wait for the full duration of effects before considering redosing — the short duration invites compulsive redosing, which rapidly accumulates respiratory risk
- Use in a physically safe position (seated or on the side, not standing)
Set & Setting
Acetylfentanyl should never be used alone. The rapid onset and narrow therapeutic index mean the window between functional consciousness and respiratory arrest is extremely short. A sober companion capable of recognizing overdose signs and administering naloxone is a minimum safety requirement. Use in unfamiliar, isolated, or physically hazardous environments compounds risk.
Aftercare & integration. Following acetylfentanyl use, physical recovery includes adequate hydration, light nutrition, and rest. Constipation is common after opioid use and may persist for 1–2 days. Monitor breathing and alertness for several hours after effects appear to subside, particularly if naloxone was administered — re-sedation is possible as naloxone wears off.
The reinforcing quality of μ-opioid agonism makes honest self-assessment essential. If use was motivated by emotional pain rather than curiosity, or if the compulsive redosing urge was difficult to resist, these patterns warrant attention before they become entrenched. Professional support is appropriate at any stage.
Recovery & Support
Acetylfentanyl dependence follows the same trajectory as other opioid dependencies: escalating use, narrowing of daily life around the substance, and withdrawal avoidance as a primary motivator. Evidence-based treatment options include:
- Medication-assisted treatment: buprenorphine (Suboxone) and methadone reduce cravings and prevent withdrawal. Naltrexone is an option after full detoxification.
- Professional detoxification: Medical supervision during withdrawal reduces risk and discomfort. Abrupt cessation without medical support is not recommended.
- Peer support: SMART Recovery, Narcotics Anonymous, and harm reduction organizations offer community-based support structures.
- Mental health care: Co-occurring depression, anxiety, and trauma are common in opioid use disorder and benefit from parallel treatment.
Recovery is not conditional on hitting a defined low point. Support resources exist at every stage.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed dramatically, become irregular, or stopped
- Lips, fingertips, or skin have turned blue or gray
- Person is unresponsive to voice, sternal rub, or pain
- Deep snoring or gurgling sounds (airway obstruction)
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone (nasal spray or injection) — do not wait to see if the person improves on their own
- 3. If no response after 2–3 minutes, administer a second dose of naloxone
- 4. Place the person in the recovery position (on their side, mouth angled downward) to prevent choking
- 5. Stay with the person — acetylfentanyl's effects may outlast naloxone's duration, causing re-sedation
- 6. Begin rescue breathing if trained and if the person is not breathing
What to tell the dispatcher:
- "Possible opioid overdose"
- What was taken (if known), how much, and when
- Whether naloxone has been given and how many doses
- Current breathing status and level of consciousness
- Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses
Reversal agent: Naloxone (Narcan) is an effective opioid antagonist that reverses acetylfentanyl's respiratory depression. Multiple doses may be required, as acetylfentanyl's effects can outlast a single naloxone dose. Naloxone is available without prescription in many jurisdictions.
Legal Status[edit]
Acetylfentanyl is controlled in most major jurisdictions, driven by documented overdose fatalities from 2013 onward and its classification as an structural analog of fentanyl. It has no approved medical use in any country.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily scheduled July 2015;[26] permanently placed June 2017 with 57+ confirmed deaths cited.[9] Prior to 2015, potentially subject to Federal Analogue Act. |
| Canada | CDSA Schedule I | Controlled under fentanyl and analogues provision.[27] A 3 kg seizure occurred in 2013.[1] |
| European Union | Subject to member state controls | EMCDDA–Europol joint risk assessment completed September 2015; joint report published June 2016.[7] Sweden, Germany, and Poland implemented controls following documented fatalities. |
| United Kingdom | Controlled | Two documented fatalities by August 2015. Covered by Psychoactive Substances Act 2016 and potentially by generic fentanyl analog provisions under the Misuse of Drugs Act 1971.citation needed |
| Australia | Expected Schedule 9 (Prohibited Substance) | Classification expected based on class membership but not independently confirmed.citation needed |
| Japan | Controlled under narcotics law | Documented fatalities and market detections from 2014–2015.[6] |
Analog and precursor considerations
Acetylfentanyl's principal metabolite, 4-ANPP, is independently controlled as a fentanyl precursor in the United States and under international conventions. Its detection in biological specimens confirms acetylfentanyl exposure.[17] Acetylfentanyl itself can be readily converted to fentanyl and is frequently detected as a manufacturing impurity in illicit fentanyl production,[3] creating regulatory complications at the intersection of analog control and precursor scheduling.
references
- [1] ^abcZawilska JB (2017) An Expanding World of Novel Psychoactive Substances: Opioids — Frontiers in Psychiatry doi:10.3389/fpsyt.2017.00110
- [2] ^abcPrekupec MP, Mansky PA, Baumann MH (2017) Misuse of Novel Synthetic Opioids: A Deadly New Trend. — Journal of addiction medicine doi:10.1097/adm.0000000000000324
- [3]
- [4] ^abcdJannetto PJ, Helander A, Garg U, Janis GC, Goldberger B, Ketha H (2019) The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union. — Clinical chemistry doi:10.1373/clinchem.2017.281626
- [5] ^abcLozier MJ, Boyd M, Stanley C, Ogilvie L, King E, Martin C, Lewis L (2015) Acetyl Fentanyl, a Novel Fentanyl Analog, Causes 14 Overdose Deaths in Rhode Island, March-May 2013. — Journal of medical toxicology doi:10.1007/s13181-015-0477-9
- [6]